Non-Small Cell Lung Cancer Study

Stage II or III A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages 2 and 3 Non-Small Cell Lung Cancer (AEGEAN)